is a TGFβ family signal transduction pathway inhibiting substance and/or a Wnt signal transduction pathway inhibiting substance.

20. The production method according to claim 19, wherein the TGFβ family signal transduction pathway inhibiting substance is Lefty, SB431542, A-83-01 or LDN193189.

21. The production method according to claim 19 or 20, wherein the Wnt signal transduction pathway inhibiting substance is IWR-1-endo.

22. The production method according to any of claims 1 to 9 or 19 to 21, wherein the aggregate obtained in the third step contains a cerebral tissue.

23. The production method according to any of claims 1 to 22, wherein a period for the culturing in the first step is 0.5 hr - 144 hr.

24. The production method according to any of claims 1 to 23, wherein the first step is performed by an adhesion culturing method.

25. The production method according to any of claims 1 to 24, wherein, in the third step, the differentiation-inducing factor is added to the medium between day 3 and day 6 after the start of the second step.

26. The production method according to any of claims 1 to 15 and 17 to 25, wherein the pluripotent stem cells are primate pluripotent stem cells.

27. The production method according to any of claims 1 to 15 and claims 17 to 26, wherein the pluripotent stem cells are human pluripotent stem

cells.

28. The production method according to any of claims 1 to 27, wherein the pluripotent stem cells are induced pluripotent stem cells.

29. The production method according to any of claims 1 to 28, wherein uniformed aggregates are formed in the second step.

30. The production method according to any of claims 1 to 29, wherein the suspension culturing is performed in the absence of a basement membrane preparation.

31. A reagent for evaluating toxicity or efficacy of a test substance, comprising neural cells or a neural tissue produced by the method according to any one of claims 1 to 30.

32. A method for evaluating toxicity or efficacy of a test substance, comprising bringing the substance into contact with neural cells or a neural tissue produced by the method according to any of claims 1 to 30, and detecting an influence of the substance on the cells or tissue.

33. A medicament for treating a disease due to a disorder of a neural cell or a neural tissue, comprising neural cells or a neural tissue produced by the method according to any of claims 1 to 30.

34. The medicament according to claim 33, wherein the neural cells or neural tissue is retinal progenitor cells, retinal layer-specific neurons, retinal tissue, cerebral neural precursor cells, cerebral layer-specific neurons, or cerebral tissue.

35. Use of neural cells or a neural tissue produced by the method according to any of claims 1 to 30 in the manufacture of a medicament for treating a disease due to a disorder of a neural cell

or a neural tissue, wherein an effective amount of the neural cells or neural tissue is to be transplanted to a subject in need of the transplantation.

36. Neural cells or a neural tissue produced by the method according to any of claims 1 to 30 for use in the treatment of a disease due to a disorder of a neural cell or a neural tissue.

37. A pharmaceutical composition comprising neural cells or a neural tissue produced by the method according to any one of claims 1 to 30 as an active ingredient.